Clinical trials patient number

In clinical trials patients are selected according to a number of inclusion and exclusion criteria. Selection criteria in a clinical trial consist of ... 

Clinical trial Purpose Number of Patients Duration Success Rate (%y... 

The patients included in clinical studies should, in general, reflect the population that will receive the drug when it is marketed. For most drugs, therefore, representatives of both sexes should be included in clinical trials in numbers adequate to allow detection of clinically significant sex-related differences in drug response. 

Daptomycin is a fermentation product having a cyclic lipopeptide structure. It is primarily active against Gram-positive infections, especially those involved in skin/skin structure infections. It is given IV but must be administered over a period of 30 minutes or more. It binds to cell membranes and causes depolarization, which interrupts protein, DNA, and RNA synthesis. Daptomycin is bactericidal. Although resistance can be achieved in vitro, resistance has been slow to emerge in the clinic. Patients should be monitored for muscle pain or weakness, because some incidence of elevated serum creatinine phosphokinase is associated with its use. A small number of clinical trial patients also developed conditions related to decreases in nerve conduction (e.g., paresthesias and Bell s palsy). Daptomycin is eliminated primarily by the kidney, so dose adjustment may be necessary in cases of renal insufficiency. 

In some medical specialties it is usual for patients to have rescue medication. For example, in asthma, many asthmatics will carry a beta-agonist in an inhaler to deal with asthma attacks. This form of emergency treatment cannot reasonably be denied them in a clinical trial. A number of analysis strategies are possible for dealing with resort to rescue medication. 

The data in support of a protective role for helminth infections in modulating inflammation poses the clinically relevant question, WiU a worm a day keep the doctor away To address this question, there are a number of completed and ongoing clinical trials that involve the deliberate infection of patients with live helminth infections (Table 3). In recent clinical trials, patients with... 

Clinical trials for r-IEN-y in RA indicated that the dmg is well tolerated (52). Consistent improvement in tender and swollen joint scores was observed, but a large number of patients were needed in the trial to show statistical significance for r-IEN-y treatment. In certain individuals, responses were remarkable. An additive effect between r-IEN-y and penicillamine was detected. Efficacy was lower when r-IEN-y was combined with gold therapy. Research is continuing. 

Data from a number of clinical cohort studies and clinical trials iUusfrates that HlV-1 is predominantly classified as R5 in tteatment-naive patients (Brumme et al. 2005 Moyle et al. 2005). In tteatment-experienced patients (with low nadir CD4- -count), there is an increase in CXCR4-using virus, which is almost entirely due to an increase in D/M virus (Moyle et al. 2005 Melby et al. 2006a). Pure X4 virus remains rare and indeed, even in treatment-experienced patients, 47-62% of patients continue to have only R5 virus. 

Limited Knowledge of Exposure and Reporting Rates in Postmarketing Data. Unlike clinical trials and electronic medical records in clinical practice, postmarketing voluntarily reported data contain limited information about the total number of patients exposed and the duration of exposure. This problem is compounded by the fact that adverse events are often underreported [2,9]. 

Only two randomized, controlled trials have been completed, and neither provides anything like compelling data (Table 2.6). Chouinard and Albright (1997) conducted a unique evaluation of a subset of patients from a previously conducted clinical trial. Subjects were categorized and profiled at baseline and end point according to clinical severity, and a group of psychiatric nurses were asked to rate various aspects of likely outcome and quality of life to each profile (mild, moderate or severe symptoms). Health state utilities were then calculated risperidone was found to provide more than double the number of quality-adjusted life years compared with haloperidol. Csernansky and Okamoto (1999) conducted a rather more conventional trial, but included no economic analyses. However, they did find that the use of risperidone substantially reduced relapse rates compared with haloperidol—an outcome likely to have a positive impact on cost-effectiveness. 

---